News from lexicon pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 08, 2017, 06:00 ET Lexicon Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides A Business Update

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2017 and provided an overview ...

Nov 03, 2017, 07:00 ET Lexicon Pharmaceuticals To Host Third Quarter 2017 Financial Results Conference Call And Webcast On November 8, 2017

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2017 financial results on Wednesday, November 8, 2017 before market...

Nov 02, 2017, 07:00 ET Lexicon Pharmaceuticals To Present At Upcoming Investor Conferences

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative...

Sep 27, 2017, 07:00 ET Lexicon Pharmaceuticals Initiates Patient Dosing In A Phase 1 Study Of LX9211

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the company has initiated dosing in a Phase 1 study of LX9211, an orally-administered...

Sep 19, 2017, 12:33 ET European Commission Approves XERMELO® (Telotristat Ethyl) For The Treatment Of Carcinoid Syndrome Diarrhea In Combination With Somatostatin Analog Therapy

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that the European Commission has approved XERMELO® (telotristat ethyl) 250 mg as a...

Sep 18, 2017, 07:00 ET Lexicon Pharmaceuticals To Present At The 2017 Cantor Fitzgerald Global Healthcare Conference

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will present at the following conference: Lonnel Coats, President and Chief...

Sep 13, 2017, 04:31 ET New England Journal Of Medicine Publishes Data From Phase 3 inTandem3 Study Of Sotagliflozin In Patients With Type 1 Diabetes

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the New England Journal of Medicine (NEJM) published the results of the Phase 3...

Sep 08, 2017, 07:00 ET Lexicon Pharmaceuticals Reports Positive Pooled Continuous Glucose Monitoring Data From Pivotal Phase 3 inTandem1 And inTandem2 Studies Of Sotagliflozin

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced positive pooled continuous glucose monitoring (CGM) data from the pivotal Phase 3...

Sep 07, 2017, 07:00 ET Lexicon Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2017 Global Healthcare Conference

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will present at the following conference: Jeffrey L. Wade, J.D., Executive Vice...

Sep 07, 2017, 07:00 ET Lexicon Pharmaceuticals Announces Four Data Presentations At The European Society Of Medical Oncology 2017 Congress

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from four posters highlighting XERMELO® (telotristat ethyl) will be presented ...

Sep 05, 2017, 07:00 ET Lexicon Pharmaceuticals to Present New Clinical Data at the European Association for the Study of Diabetes 53rd Annual Meeting

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that new clinical data for sotagliflozin will be presented at the upcoming European...

Aug 15, 2017, 07:00 ET Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal Phase 3 inTandem2 Study Of Sotagliflozin

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today additional positive data from the pivotal Phase 3 inTandem2 study of sotagliflozin, an...

Aug 03, 2017, 07:00 ET Lexicon Pharmaceuticals To Present At 2017 Wedbush PacGrow Healthcare Conference

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will present at the following conference: Jeffrey L. Wade, J.D., Executive Vice...

Aug 01, 2017, 07:00 ET Lexicon Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides A Business Update

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2017 and provided an overview of...

Jul 31, 2017, 18:01 ET Lexicon Pharmaceuticals Announces Opt-In Decision For U.S. Co-Promotion Of Sotagliflozin With Sanofi In Type 1 Diabetes

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that it has exercised its option under its collaboration and license agreement with...

Jul 24, 2017, 09:00 ET Lexicon Pharmaceuticals To Host Second Quarter 2017 Financial Results Conference Call And Webcast On August 1, 2017

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2017 financial results on Tuesday, August 1, 2017 before market opens....

Jul 21, 2017, 07:27 ET Lexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo® (Telotristat Ethyl)

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that the Committee for Medicinal Products for Human Use (CHMP), the committee of the...

Jun 19, 2017, 07:00 ET NCCN Guidelines For Neuroendocrine Tumors Include XERMELO In Combination With Somatostatin Analog Therapy As A Recommended Treatment Option For Patients With Carcinoid Syndrome Diarrhea

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that XERMELO™ (telotristat ethyl) 250 mg has been included as a recommended treatment...

Jun 10, 2017, 13:01 ET Sotagliflozin Data from Pivotal inTandem1 and inTandem2 Studies in Patients with Type 1 Diabetes Presented at ADA 2017

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced data from its two pivotal sotagliflozin studies, inTandem1 and inTandem2, being...

Jun 09, 2017, 07:01 ET Lexicon Pharmaceuticals Reports Positive Top-Line Results In Phase 3 inTandem3 Study For Sotagliflozin In Patients With Type 1 Diabetes

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced positive top-line results from its Phase 3 inTandem3 study of sotagliflozin, an...

Jun 05, 2017, 16:01 ET Lexicon Pharmaceuticals To Present New Clinical Data At 77th American Diabetes Association Scientific Sessions

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that new clinical data for sotagliflozin will be presented at the upcoming 77th American ...

May 31, 2017, 13:15 ET Lexicon Pharmaceuticals To Present At Upcoming Investor Conferences

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will present at the following conferences: Jeffrey L. Wade, J.D., Executive Vice ...

May 11, 2017, 06:30 ET Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal InTandem1 Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today additional positive data from the Phase 3 inTandem1 study. It was previously announced...

May 04, 2017, 15:09 ET Lexicon Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2017 Healthcare Conference

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will present at the following conference: Jeffrey L. Wade, Executive Vice...

May 02, 2017, 16:44 ET Lexicon Pharmaceuticals Reports First Quarter 2017 Financial Results And Provides A Business Update

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2017 and provided an overview of...